p53 and Its Isoforms in Renal Cell Carcinoma—Do They Matter?
Abstract
:1. Introduction
2. Wild-Type and Mutant p53 in Renal Cell Carcinoma
2.1. Wild Type p53 and Von Hippel–Lindau—Alone and Together
2.2. Mutant p53 and Clinical Prognosis for RCC Patients
3. p53 Isoforms in RCC
4. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hsieh, J.J.; Le, V.; Cao, D.; Cheng, E.H.; Creighton, C.J. Genomic classifications of renal cell carcinoma: A critical step towards the future application of personalized kidney cancer care with pan-omics precision. J. Pathol. 2018, 244, 525–537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cairns, P. Renal cell carcinoma. Cancer Biomark 2011, 9, 461–473. [Google Scholar] [CrossRef] [PubMed]
- Ooms, A.H.; Gadd, S.; Gerhard, D.S.; Smith, M.A.; Auvil, J.M.G.; Meerzaman, D.; Chen, Q.-R.; Hsu, C.H.; Yan, C.; Nguyen, C.; et al. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children’s Oncology Group. Clin. Cancer Res. 2016, 22, 5582–5591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, F.; Aljahdali, I.A.M.; Zhang, R.; Nastiuk, K.L.; Krolewski, J.J.; Ling, X. Kidney cancer biomarkers and targets for therapeutics: Survivin (BIRC5), XIAP, MCL-1, HIF1alpha, HIF2alpha, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J. Exp. Clin. Cancer Res. 2021, 40, 254. [Google Scholar] [CrossRef]
- Hsieh, J.J.; Le, V.H.; Oyama, T.; Ricketts, C.J.; Ho, T.H.; Cheng, E.H. Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. J. Clin. Oncol. 2018, 36, 3533–3539. [Google Scholar] [CrossRef] [PubMed]
- Nickerson, M.L.; Jaeger, E.; Shi, Y.; Durocher, J.A.; Mahurkar, S.; Zaridze, D.; Matveev, V.; Janout, V.; Kollárová, H.; Bencko, V.; et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 2008, 14, 4726–4734. [Google Scholar] [CrossRef] [Green Version]
- Kaelin, W.G. Von Hippel-Lindau disease. Annu. Rev. Pathol. 2007, 2, 145–173. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Zhang, L.; Zhang, X.; Yan, Q.; Minamishima, Y.A.; Olumi, A.F.; Mao, M.; Bartz, S.; Kaelin, W.G. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol. Cell. Biol. 2007, 27, 5381–5392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kastenhuber, E.R.; Lowe, S.W. Putting p53 in Context. Cell 2017, 170, 1062–1078. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Menendez, D.; Nguyen, T.-A.; Freudenberg, J.M.; Mathew, V.J.; Anderson, C.W.; Jothi, R.; Resnick, M.A. Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res. 2013, 41, 7286–7301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aubrey, B.J.; Kelly, G.L.; Janic, A.; Herold, M.J.; Strasser, A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018, 25, 104–113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baugh, E.H.; Ke, H.; Levine, A.J.; Bonneau, R.A.; Chan, C.S. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018, 25, 154–160. [Google Scholar] [CrossRef]
- Coffill, C.R.; Muller, P.A.J.; Oh, H.K.; Neo, S.P.; Hogue, K.A.; Cheok, C.F.; Vousden, K.H.; Lane, D.; Blackstock, W.P.; Gunaratne, J. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep. 2012, 13, 638–644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mantovani, F.; Collavin, L.; Del Sal, G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019, 26, 199–212. [Google Scholar] [CrossRef]
- Swiatkowska, A.; Dutkiewicz, M.; Zydowicz-Machtel, P.; Szpotkowska, J.; Janecki, D.M.; Ciesiołka, J. Translational Control in p53 Expression: The Role of 5′-Terminal Region of p53 mRNA. Int. J. Mol. Sci. 2019, 20, 5382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaelin, W.G. The von Hippel-Lindau tumor suppressor protein: Roles in cancer and oxygen sensing. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 159–166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Semenza, G.L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 2003, 54, 17–28. [Google Scholar] [CrossRef]
- Pezzuto, A.; Carico, E. Role of HIF-1 in Cancer Progression: Novel Insights. A Review. Curr. Mol. Med. 2018, 18, 343–351. [Google Scholar] [CrossRef]
- Schoenfeld, A.R.; Parris, T.; Eisenberger, A.; Davidowitz, E.J.; De Leon, M.; Talasazan, F.; Devarajan, P.; Burk, R.D. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 2000, 19, 5851–5857. [Google Scholar] [CrossRef] [Green Version]
- Gurova, K.V.; Hill, J.; Razorenova, O.V.; Chumakov, P.; Gudkov, A. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res. 2004, 64, 1951–1958. [Google Scholar] [CrossRef] [Green Version]
- Roe, J.-S.; Kim, H.; Lee, S.-M.; Kim, S.-T.; Cho, E.-J.; Youn, H.-D. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell 2006, 22, 395–405. [Google Scholar] [CrossRef]
- Roe, J.S.; Youn, H.D. The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle 2006, 5, 2054–2056. [Google Scholar] [CrossRef] [Green Version]
- Ziello, J.E.; Jovin, I.S.; Huang, Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J. Biol. Med. 2007, 80, 51–60. [Google Scholar] [PubMed]
- Zhao, Z.; Chen, C.; Lin, J.; Zeng, W.; Zhao, J.; Liang, Y.; Tan, Q.; Yang, C.; Li, H. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma. Mol. Med. Rep. 2016, 14, 2785–2790. [Google Scholar] [CrossRef] [Green Version]
- Diesing, K.; Ribback, S.; Winter, S.; Gellert, M.; Oster, A.M.; Stühler, V.; Gläser, E.; Adler, F.; Hartwig, C.; Scharpf, M.; et al. p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): A mechanistic and correlative investigation into genetic and molecular characteristics. J. Cancer Res. Clin. Oncol. 2021, 147, 3565–3576. [Google Scholar] [CrossRef] [PubMed]
- Cai, W.; Su, L.; Liao, L.; Liu, Z.Z.; Langbein, L.; Dulaimi, E.; Testa, J.R.; Uzzo, R.G.; Zhong, Z.; Jiang, W.; et al. PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nat. Commun. 2019, 10, 5800. [Google Scholar] [CrossRef]
- Xie, H.; Ma, K.; Zhang, K.; Zhou, J.; Li, L.; Yang, W.; Gong, Y.; Cai, L.; Gong, K. Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway. Cell Death Dis. 2021, 12, 1. [Google Scholar] [CrossRef]
- Wang, D.; Garcia-Bassets, I.; Benner, C.; Li, W.; Su, X.; Zhou, Y.; Qiu, J.; Liu, W.; Kaikkonen, M.; Ohgi, K.A.; et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011, 474, 390–394. [Google Scholar] [CrossRef] [Green Version]
- Melo, C.A.; Drost, J.; Wijchers, P.J.; van de Werken, H.; de Wit, E.; Vrielink, J.A.O.; Elkon, R.; Melo, S.; Léveillé, N.; Kalluri, R.; et al. eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol. Cell 2013, 49, 524–535. [Google Scholar] [CrossRef] [Green Version]
- Zhang, C.; Liu, J.; Liang, Y.; Wu, R.; Zhao, Y.; Hong, X.; Lin, M.; Yu, H.; Liu, L.; Levine, A.J.; et al. Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun. 2013, 4, 2935. [Google Scholar] [CrossRef] [Green Version]
- Lisek, K.; Campaner, E.; Ciani, Y.; Walerych, D.; Del Sal, G. Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. Oncotarget 2018, 9, 20508–20523. [Google Scholar] [CrossRef] [Green Version]
- Polotskaia, A.; Xiao, G.; Reynoso, K.; Martin, C.; Qiu, W.-G.; Hendrickson, R.C.; Bargonetti, J. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc. Natl. Acad. Sci. USA 2015, 112, E1220–E1229. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Zhao, Y.; Sun, P.; Zhao, M.; Su, Z.; Jin, X.; Song, W. p53beta: A new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median follow-up. Carcinogenesis 2018, 39, 368–374. [Google Scholar] [CrossRef] [PubMed]
- Uhlman, D.L.; Nguygen, P.L.; Manivel, J.C.; Aeppli, D.; Resnick, J.M.; Fraley, E.E.; Zhang, G.; Niehans, G.A. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J. Natl. Cancer Inst. 1994, 86, 1470–1475. [Google Scholar] [CrossRef]
- Fischer, N.W.; Prodeus, A.; Malkin, D.; Gariepy, J. p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis. Cell Cycle 2016, 15, 3210–3219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walerych, D.; Pruszko, M.; Zyla, L.; Wezyk, M.; Gaweda-Walerych, K.; Zylicz, A. Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a “dominant-positive” mechanism. Oncotarget 2018, 9, 32063–32080. [Google Scholar] [CrossRef] [PubMed]
- Lang, V.; Pallara, C.; Zabala, A.; Lobato-Gil, S.; Lopitz-Otsoa, F.; Farrás, R.; Hjerpe, R.; Torres-Ramos, M.; Zabaleta, L.; Blattner, C.; et al. Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity. Mol. Oncol. 2014, 8, 1026–1042. [Google Scholar] [CrossRef]
- Guha, T.; Malkin, D. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. Cold Spring Harb. Perspect. Med. 2017, 7, a026187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morshaeuser, L.; May, M.; Burger, M.; Otto, W.; Hutterer, G.C.; Pichler, M.; Klatte, T.; Wild, P.; Buser, L.; Brookman-May, S. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models. Urol. Oncol. 2018, 36, 94.e15–94.e21. [Google Scholar] [CrossRef] [PubMed]
- Voss, M.H.; Reising, A.; Cheng, Y.; Patel, P.; Marker, M.; Kuo, F.; Chan, T.A.; Choueiri, T.K.; Hsieh, J.J.; Hakimi, A.A.; et al. Genomically annotated risk model for advanced renal-cell carcinoma: A retrospective cohort study. Lancet Oncol. 2018, 19, 1688–1698. [Google Scholar] [CrossRef]
- Wang, Z.; Peng, S.; Jiang, N.; Wang, A.; Liu, S.; Xie, H.; Guo, L.; Cai, Q.; Niu, Y. Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: A meta-analysis. Oncotarget 2017, 8, 102361–102370. [Google Scholar] [CrossRef] [Green Version]
- Noon, A.P.; Vlatkovic, N.; Polanski, R.; Shawki, H.; Parsons, K.; Boyd, M.T. p53 and MDM2 in renal cell carcinoma: Biomarkers for disease progression and future therapeutic targets? Cancer 2010, 116, 780–790. [Google Scholar] [CrossRef] [Green Version]
- Torras, O.R.; Mishra, A.; Christie, A.; McKenzie, T.; Onabolu, O.; Singla, N.; Plimack, E.R.; Suárez, C.; Ornstein, M.C.; Alpaugh, R.K.; et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur. Urol. 2021, 81, 555–558. [Google Scholar] [CrossRef] [PubMed]
- Lee, D.; Kim, J.W.; Seo, T.; Hwang, S.G.; Choi, E.-J.; Choe, J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J. Biol. Chem. 2002, 277, 22330–22337. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khoury, M.P.; Bourdon, J.C. The isoforms of the p53 protein. Cold Spring Harb. Perspect. Biol 2010, 2, a000927. [Google Scholar] [CrossRef] [Green Version]
- Joruiz, S.M.; Bourdon, J.C. p53 Isoforms: Key Regulators of the Cell Fate Decision. Cold Spring Harb. Perspect. Med. 2016, 6, a026039. [Google Scholar] [CrossRef] [Green Version]
- Beck, J.; Turnquist, C.; Horikawa, I.; Harris, C. Targeting cellular senescence in cancer and aging: Roles of p53 and its isoforms. Carcinogenesis 2020, 41, 1017–1029. [Google Scholar] [CrossRef] [PubMed]
- Marcel, V.; Fernandes, K.; Terrier, O.; Lane, D.P.; Bourdon, J.-C. Modulation of p53beta and p53gamma expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ. 2014, 21, 1377–1387. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Avery-Kiejda, K.A.; Morten, B.; Wong-Brown, M.W.; Mathe, A.; Scott, R.J. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis 2014, 35, 586–596. [Google Scholar] [CrossRef]
- Anensen, N.; Oyan, A.M.; Bourdon, J.-C.; Kalland, K.H.; Bruserud, O.; Gjertsen, B.T. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin. Cancer Res. 2006, 12, 3985–3992. [Google Scholar] [CrossRef] [Green Version]
- Courtois, S.; Verhaegh, G.; North, S.; Luciani, M.-G.; Lassus, P.; Hibner, U.; Oren, M.; Hainaut, P. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002, 21, 6722–6728. [Google Scholar] [CrossRef] [Green Version]
- Steffens Reinhardt, L.; Zhang, X.; Wawruszak, A.; Groen, K.; Iuliis, G.N.D.; Avery-Kiejda, K.A. Good Cop, Bad Cop: Defining the Roles of Delta40p53 in Cancer and Aging. Cancers 2020, 12, 1659. [Google Scholar] [CrossRef]
- Swiatkowska, A.; Zydowicz, P.; Górska, A.; Suchacka, J.; Dutkiewicz, M.; Ciesiołka, J. The Role of Structural Elements of the 5′-Terminal Region of p53 mRNA in Translation under Stress Conditions Assayed by the Antisense Oligonucleotide Approach. PLoS ONE 2015, 10, e0141676. [Google Scholar] [CrossRef]
- Hafsi, H.; Santos-Silva, D.; Courtois-Cox, S.; Hainaut, P. Effects of Delta40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. BMC Cancer 2013, 13, 134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ohki, R.; Kawase, T.; Ohta, T.; Ichikawa, H.; Taya, Y. Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis. Cancer Sci. 2007, 98, 189–200. [Google Scholar] [CrossRef]
- Joruiz, S.M.; Beck, J.A.; Horikawa, I.; Harris, C.C. The Delta133p53 Isoforms, Tuners of the p53 Pathway. Cancers 2020, 12, 3422. [Google Scholar] [CrossRef] [PubMed]
- Zydowicz-Machtel, P.; Dutkiewicz, M.; Swiatkowska, A.; Gurda-Woźna, D.; Ciesiołka, J. Translation of human Delta133p53 mRNA and its targeting by antisense oligonucleotides complementary to the 5′-terminal region of this mRNA. PLoS ONE 2021, 16, e0256938. [Google Scholar] [CrossRef]
- Horikawa, I.; Park, K.-Y.; Li, H.; Isogaya, K.; Hiyoshi, Y.; Anami, K.; Robles, A.I.; Mondal, A.M.; Fujita, K.; Serrano, M.; et al. Delta133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells. Cell Death Differ. 2017, 24, 1017–1028. [Google Scholar] [CrossRef]
- Gong, L.; Pan, X.; Yuan, Z.M.; Peng, J.; Chen, J. p53 coordinates with Delta133p53 isoform to promote cell survival under low-level oxidative stress. J. Mol. Cell Biol. 2016, 8, 88–90. [Google Scholar] [CrossRef] [Green Version]
- Vieler, M.; Sanyal, S. p53 Isoforms and Their Implications in Cancer. Cancers 2018, 10, 288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fujita, K.; Mondal, A.M.; Horikawa, I.; Nguyen, G.N.; Kumamoto, K.; Sohn, J.J.; Bowman, E.D.; Mathe, E.A.; Schetter, A.J.; Pine, S.R. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat. Cell Biol. 2009, 11, 1135–1142. [Google Scholar] [CrossRef]
- Marcel, V.; Perrier, S.; Aoubala, M.; Ageorges, S.; Groves, M.J.; Diot, A.; Fernandes, K.; Tauro, S.; Bourdon, J.-C. Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. FEBS Lett. 2010, 584, 4463–4468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tadijan, A.; Precazzini, F.; Hanžić, N.; Radić, M.; Gavioli, N.; Vlašić, I.; Ozretić, P.; Pinto, L.; Škreblin, L.; Barban, G.; et al. Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness. Cancers 2021, 13, 5231. [Google Scholar] [CrossRef]
- Candeias, M.M.; Hagiwara, M.; Matsuda, M. Cancer-specific mutations in p53 induce the translation of Delta160p53 promoting tumorigenesis. EMBO Rep. 2016, 17, 1542–1551. [Google Scholar] [CrossRef] [PubMed]
- Heikaus, S.; Berg, L.V.D.; Segun, A.D.; Mersch, S.; Blasberg, N.; Grinstein, E.; Wai, D.; Anlauf, M.; Gabbert, H.E.; Mahotka, C. Regulation of p53 isoform expression in renal cell carcinoma. Front. Biosci. 2010, 2, 1042–1053. [Google Scholar] [CrossRef]
- Knezovic Florijan, M.; Ozretic, P.; Bujak, M.; Pezzè, L.; Ciribilli, Y.; Kaštelan; Slade, N.; Hudolin, T. The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urol. Oncol. 2019, 37, 578.e1–578.e10. [Google Scholar] [CrossRef] [PubMed]
- Chasov, V.; Zaripov, M.; Mirgayazova, R.; Khadiullina, R.; Zmievskaya, E.; Ganeeva, I.; Valiullina, A.; Rizvanov, A.; Bulatov, E. Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies. Front. Immunol. 2021, 12, 707734. [Google Scholar] [CrossRef]
- Beloglazkina, A.; Zyk, N.; Majouga, A.; Beloglazkina, E. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction. Molecules 2020, 25, 1211. [Google Scholar] [CrossRef] [Green Version]
Kidney | ccRCC | chRCC | pRCC | |
---|---|---|---|---|
Total samples tested | 4766 | 2303 | 203 | 405 |
Total mutated samples | 417 (395) * | 155 (136) * | 53 | 8 |
Total percentage of samples mutated [%] | 8.75 | 6.73 | 25.62 | 1.98 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Swiatkowska, A. p53 and Its Isoforms in Renal Cell Carcinoma—Do They Matter? Biomedicines 2022, 10, 1330. https://doi.org/10.3390/biomedicines10061330
Swiatkowska A. p53 and Its Isoforms in Renal Cell Carcinoma—Do They Matter? Biomedicines. 2022; 10(6):1330. https://doi.org/10.3390/biomedicines10061330
Chicago/Turabian StyleSwiatkowska, Agata. 2022. "p53 and Its Isoforms in Renal Cell Carcinoma—Do They Matter?" Biomedicines 10, no. 6: 1330. https://doi.org/10.3390/biomedicines10061330